We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk outline
- Cancer staging
- Treatment options
- Evolution of cancer treatment: surgery
- Surgery: role in cancer treatment
- Evolution of cancer treatment: radiation
- Radiation therapy
- Radiation: role in cancer
- Evolution of cancer treatment: chemotherapy
- Factors influencing efficacy of chemotherapy
- Combination chemotherapy
- Role of chemotherapy
- Neoadjuvant vs. adjuvant
- Chemotherapy administration
- Local/regional routes of chemo administration
- Evaluating effects of chemotherapy
- Common clinical trial endpoints
- Evolution of cancer treatment: targteted therapy
- Why do cancer cells grow?
- EGFR signaling pathway
- Crosstalk and collaboration
- Chronic myelogenous leukemia (CML)
- Tyrosine kinase approvals for CML
- Common oncogene targets
- Targeted therapy
- Common monoclonal antibodies
- Monoclonal antibodies: suffixes
- Monoclonal antibodies: compositions
- Monoclonal antibodies: targets
- Antibody-drug conjugates
- Trastuzumab emtansine (T-DM1)
- Radiolabeled monoclonal antibodies
- Ibritumomab tiuxetan
Topics Covered
- Localized and systemic therapy options used in cancer treatment
- Chemotherapy delivery and factors influencing efficacy
- Common cancer targets and related therapies
- Basic pharmacology of targeted therapy options
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Walko, C.M. (2017, May 29). Key considerations for cancer pharmacotherapy 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 6, 2024, from https://doi.org/10.69645/OYCY3508.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Christine M. Walko has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Key considerations for cancer pharmacotherapy 1
Published on May 29, 2017
42 min
Other Talks in the Series: Cancer Therapies in the Personalized Medicine Era
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Chris Walko
and I am a personalized medicine specialist
at Moffitt Cancer Center
in Tampa, Florida in the United States.
And today we're going to be discussing
the treatment paradigms
used to treat cancer
and I'm going to aim to provide
an overview of key considerations
for cancer pharmacotherapies.
I've worked in the oncology realm
for more than 10 years
as a pharmacist
and a clinical pharmacist and an educator
and now my role is actually
in chairing a Molecular Tumor Board
and helping to use cancer genetics
to personalize therapy
in direct treatment.
0:38
So I'm really excited to see
how we translate
all of what we've learned over the years
and throughout this lecture
we're going to talk a little bit
about the history
of how we've treated cancer
and ultimately end up with
kind of where we are today
with the targeted therapies intermixed
with the cytotoxic therapies
and the immunotherapies.
So we will review
this different treatment modalities
used to treat cancer in this section
including both local therapy,
so radiation and surgery
as well as systemic therapies.
And we will also begin to delve
into the newer targeted therapies
and the immunotherapies as I said.
This lecture is meant
to provide an overview
that will be further translated
into specific malignancies
in the subsequent learning module.
1:23
Initial cancer workup of solid tumors
includes imaging
that will help
with the staging of cancer, ascertain
if it is localized or if it is metastatic
and whether it has spread
to distant organs.
Hematologic tumors
are staged differently
given that it's the neoplastic cells
that are in the blood and the lymph nodes
and bone marrow biopsy is typically used
to provide a diagnosis in these situations.
The specific pathologic diagnosis
and extent of the disease
will help to frame our treatment goals.
The goal of localized cancer therapy
is typically to cure
whereas cancers that have spread
to different organs may not be curable.
So treatment aims are to control
disease growth and symptoms
while also maximizing quality of life.
Since this module is an overview,
generalities are going to be made
but there are always exceptions.
Some cancers are still curable
even when metastatic.
Testicular cancer
is a great example of this
if you remember the story
of Lance Armstrong
who did have testicular cancer
that had gone to multiple areas
of his body including his brain.
It's a very responsive cancer
to chemotherapy
and so, therefore, it can be cured,
so there are exceptions,
but we're going to be talking in general
and then the different disease modules
after this will go
into more specific details.